DrugPatentWatch Database Preview

Details for Patent: 8,114,909

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,114,909 protect, and when does it expire?

Patent 8,114,909 protects HORIZANT and is included in one NDA.

This patent has twenty-two patent family members in fifteen countries.

Summary for Patent: 8,114,909

Title:	Treating or preventing restless legs syndrome using prodrugs of GABA analogs
Abstract:	Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.
Inventor(s):	Barrett; Ronald W. (Saratoga, CA), Canafax; Daniel M. (Half Moon Bay, CA)
Assignee:	XenoPort, Inc. (Santa Clara, CA)
Application Number:	10/969,196
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 8,114,909

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Arbor Pharms Llc	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-002	Dec 13, 2011		RX	Yes	No						TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
Arbor Pharms Llc	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-001	Apr 6, 2011		RX	Yes	Yes						TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

International Family Members for US Patent 8,114,909

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004274002
Brazil	PI0414481
Canada	2538802
China	1871021
European Patent Office	1677812
Israel	174282